Information Provided By: 
Fly News Breaks for March 5, 2019
BLUE
Mar 5, 2019 | 07:59 EDT
As previously reported, SVB Leerink analyst Mani Foroohar downgraded Bluebird Bio to Market Perform from Outperform, with a $145 price target. While the analyst remains optimistic on the company's ability to secure approval for BCMA, Lenti-D, and LentiGlobin programs, he believes the current valuation reflects these attractive fundamentals in line with his high probability of success assumptions.
News For BLUE From the Last 2 Days
There are no results for your query BLUE
